Hindustan Laboratories Files DRHP With SEBI for Proposed IPO

Hindustan Laboratories Ltd, a Mumbai-based pharmaceutical company specialising in the manufacture and supply of generic medicines, has filed its Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI), indicating its plans to tap the primary market through an initial public offering (IPO).

The proposed IPO comprises the issuance of up to 1.41 crore equity shares with a face value of ₹10 each. The offer includes a fresh issue of up to 50 lakh shares, along with an offer for sale (OFS) of up to 91 lakh shares by existing shareholders, including the company’s promoters.

The company plans to utilise the net proceeds from the fresh issue primarily to meet its working capital requirements and for general corporate purposes.

Hindustan Laboratories operates largely under a business-to-government (B2G) model, supplying generic pharmaceutical products to central and state government agencies through public procurement tenders. Its product portfolio spans multiple therapeutic areas, including antidiabetics, cardiovascular drugs, antifungals, pain management, antihistamines, and nutritional supplements.

For the six months ended September 30, 2025, the company supplied medicines across 27 states and Union Territories, highlighting its extensive reach within India’s public healthcare system.

Further details, such as the price band, issue size, bidding dates, and allotment structure, will be announced after SEBI completes its review of the draft offer document.